Patient-Reported Outcomes in Advanced Renal Cell Carcinoma
Posted: Thursday, February 21, 2019
Compared with sunitinib treatment, combination immunotherapy with nivolumab plus ipilimumab may improve quality of life among patients with previously untreated, advanced or metastatic renal cell carcinoma with a clear cell component. The study, conducted by David Cella, PhD, of Hanover Medical School, Germany, focused on patient-reported outcomes from the phase III CheckMate 214 trial. Their findings were published in The Lancet Oncology.
The study was conducted between October 2014 and February 2016. Patients from 175 hospitals and cancer centers in 28 countries were placed into risk subgroups of favorable, intermediate, and poor. Of the 1,390 patients screened, 1,096 patients were randomly assigned to treatment: nivolumab at 3mg/kg plus ipilimumab at 1 mg/kg every 3 weeks for 4 doses followed by nivolumab at 3 mg/kg every 2 weeks (n = 425) or sunitinib at 50 mg/d for 4 weeks of each 6-week cycle (n = 422). The majority of patients (77%) had intermediate- or poor-risk disease. The median duration of treatment was 7 to 9 months.
The treatment with nivolumab and ipilimumab was found to result in fewer symptoms and better health-related quality of life than treatment with sunitinib in the patients with intermediate- or poor-risk advanced renal cell carcinoma. “Regardless of the patient-reported outcomes instrument and analysis, all patient-reported outcomes–related findings consistently favored nivolumab plus ipilimumab over sunitinib,” the investigators noted.
“These results lend further support to the benefit-risk profile of nivolumab plus ipilimumab over sunitinib as a new standard of care for first-line, advanced renal cell carcinoma,” Dr. Cella and colleagues concluded.
Disclosure: The study authors’ disclosure information may be found at thelancet.com.